Phase III Safety and Immunogenicity Study of 13-Valent Pneumococcal Conjugate Vaccine in Healthy

This Phase 3 study assesses the safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd in a pediatric population. Eligible participants are healthy infants and children aged 2 months (minimum 6 weeks) to under 6 years (before their 6th birthday). The trial is designed as an interventional study with the primary purpose of prevention of pneumococcal disease and aims to demonstrate the vaccine’s immunogenicity and safety profile. Enrollment is anticipated to include about 3,080 participants. The study is currently recruiting, with an estimated completion date in 2026. Specific safety and immunogenicity endpoints, dosing schedules, comparator groups, and statistical analysis plans are not provided in the available summary. Therefore, the interpretation of outcomes remains contingent on forthcoming trial publication. If data become available, additional details on serotype-specific responses, reactogenicity, and long-term durability would be necessary to fully assess clinical implications. Uncertainty: exact dosing regimen, booster requirements, and predefined noninferiority or superiority criteria are not specified in the provided summary.